Pfizer Covid vaccine protects adolescents against multisystem inflammatory syndrome, CDC says

- Advertisement -


  • The Centers for Disease Control and Prevention found that the Pfizer vaccine was 91% effective in protecting adolescents from multisystem inflammatory syndrome, or MIS-C.
  • MIS-C is a serious condition strongly associated with COVID infection.
  • MIS-C affects organs such as the heart, lungs, kidneys, brain, skin, eyes or gastrointestinal organs.
  • The CDC study was conducted when Delta was the dominant variant.

- Advertisement -

A new study has found that two doses of vaccines from Pfizer and BioNTech are highly effective in protecting children aged 12 to 18 years from severe inflammatory conditions associated with COVID infection.

- Advertisement -

The Centers for Disease Control and Prevention found a report published Friday that Pfizer’s vaccination was 91% effective in protecting adolescents from multisystem inflammatory syndrome, known as MIS-C.

The CDC study looked at 283 hospitalized patients aged 12 to 18 years at 24 pediatric hospitals in 20 states from July to December 2021, when Delta was the predominant form. The analysis focused on the age group of 12 to 18 years because Pfizer shots were not available for young children as of November.

- Advertisement -

The CDC notes that the efficacy of the vaccine against MIS-C due to the Omicron variant, which is now dominant in the US, could not be determined due to the timing of the study.

CNBC Health & Science

Read CNBC’s latest global coverage of the COVID pandemic:

Kovid Hospitalized in New York City, but Fewer Patients in ICU

Supreme Court to hear challenges to Biden vaccine mandate

Moderna’s CEO warns people may need a fourth COVID shot as the booster’s efficacy is likely to decline over time

CDC approves Pfizer booster for 12 to 15-year-olds amid Omicron surge

Live Update of CDC Meeting on Pfizer’s Covid Booster Shots for Teenagers

Omicron may peak or be ‘plateau’ in some parts of world, giving experts reason for optimism

MIS-C is a serious condition in which various parts of the body become inflamed, such as the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. According to the CDC, children usually develop MIS-C two to six weeks after an asymptomatic or mild COVID infection.

Since May 2020, more than 6,000 children have developed MIS-C and 55 have died, according to CDC data. The majority of MIS-C patients are Hispanic or black, the majority are boys, and half are between the ages of 5 and 13. According to the CDC, 98% of known MIS-C cases tested positive for COVID, while another 2% had exposure to the virus.

The CDC study compared 102 hospitalized MIS-C patients with 181 patients who either tested negative for COVID or had no symptoms. The majority of MIS-C patients, 95%, were not vaccinated. None of the fully vaccinated MIS-C patients required life support, whereas 39% of the unvaccinated MIS-C patients required life support.

The CDC concluded in its Morbidity and Mortality Weekly Report, “This analysis provides supporting evidence that immunization of children and adolescents is highly protective against MIS-C and COVID-19 and the importance of immunizing all eligible children.” underlines.”

Children 5 years of age and older are eligible to receive the two-dose Pfizer vaccine. Teens 12 years of age and older are eligible for Pfizer booster shots for at least five months after their second dose.

,

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox